Literature DB >> 7885127

Comparison of women who do and do not have amniocentesis or chorionic villus sampling.

J Halliday1, J Lumley, L Watson.   

Abstract

Even in areas where prenatal diagnostic testing is offered at no cost to women over a certain age, uptake of testing is not complete. We have studied the factors that affect uptake in Victoria, Australia. In 1988-92, 43% of 37-39-year-old women and 29% of those 40 years and over had no diagnostic testing despite their eligibility for a free test. We compared the characteristics of untested women (n = 3074) with those of tested women (2462 amniocentesis, 1575 chorionic villus sampling) by use of record-linkage between the Victorian birth register and fetal diagnosis data collection. The indication for testing was maternal age alone. Women who had had 3 or more previous births were less likely than those of lower parity to undergo testing (odds ratio 0.54 [95% CI 0.46-0.63], p < 0.001), whereas those who had had a previous termination of pregnancy were more likely to be tested than those who had not (1.52 [1.26-1.83], p < 0.001). Women born in non-English-speaking countries and women who lived in rural areas were less likely to be tested. Women who gave birth in private hospitals were more likely to be tested than those who gave birth in any public hospital or at home. These data help to distinguish between issues of choice and access to diagnostic testing. Factors that hinder testing of rural women and of those from non-English-speaking backgrounds should be addressed.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  1995        PMID: 7885127     DOI: 10.1016/s0140-6736(95)90872-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  Socioeconomic barriers to informed decisionmaking regarding maternal serum screening for down syndrome: results of the French National Perinatal Survey of 1998.

Authors:  Babak Khoshnood; Béatrice Blondel; Catherine de Vigan; Gérard Bréart
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

2.  Prenatal genetic testing: an investigation of determining factors affecting the decision-making process.

Authors:  Monica Pivetti; Giannino Melotti
Journal:  J Genet Couns       Date:  2012-04-03       Impact factor: 2.537

3.  Increasing total prevalence rate of cases with Down syndrome in Hungary.

Authors:  Julia Métneki; Andrew E Czeizel
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Effect of parity, gravidity, previous miscarriage, and age on risk of Down's syndrome: population based study.

Authors:  A Chan; K A McCaul; R J Keane; E A Haan
Journal:  BMJ       Date:  1998-10-03

5.  Trade-offs in prenatal detection of Down syndrome.

Authors:  M Serra-Prat; P Gallo; A J Jovell; M Aymerich; M D Estrada
Journal:  Am J Public Health       Date:  1998-04       Impact factor: 9.308

6.  Embodied Knowledge and Making Sense of Prenatal Diagnosis.

Authors:  A Lippman
Journal:  J Genet Couns       Date:  1999-10       Impact factor: 2.537

7.  Monitoring systems to evaluate the quality of perinatal care.

Authors:  J Lumley
Journal:  Soz Praventivmed       Date:  1995

8.  Advances in medical technology and creation of disparities: the case of Down syndrome.

Authors:  Babak Khoshnood; Catherine De Vigan; Véronique Vodovar; Gérard Bréart; François Goffinet; Béatrice Blondel
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

9.  Evaluation of a decision aid for prenatal testing of fetal abnormalities: a cluster randomised trial [ISRCTN22532458].

Authors:  Cate Nagle; Sharon Lewis; Bettina Meiser; Sylvia Metcalfe; John B Carlin; Robin Bell; Jane Gunn; Jane Halliday
Journal:  BMC Public Health       Date:  2006-04-13       Impact factor: 3.295

10.  Health behaviour modelling for prenatal diagnosis in Australia: a geodemographic framework for health service utilisation and policy development.

Authors:  Evelyne E Muggli; David McCloskey; Jane L Halliday
Journal:  BMC Health Serv Res       Date:  2006-09-01       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.